Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 12;8(10):e11013.
doi: 10.1016/j.heliyon.2022.e11013. eCollection 2022 Oct.

3-Deoxysappanchalcone isolated from Caesalpinia sinensis shows anticancer effects on HeLa and PC3 cell lines: invasion, migration, cell cycle arrest, and signaling pathway

Affiliations
Free PMC article

3-Deoxysappanchalcone isolated from Caesalpinia sinensis shows anticancer effects on HeLa and PC3 cell lines: invasion, migration, cell cycle arrest, and signaling pathway

Dian Lv et al. Heliyon. .
Free PMC article

Abstract

To study the antitumor activity of compound 3-desoxysulforaphane (3-DSC) isolated from Caesalpinia sinensis, SRB assay, clone formation assay, flow cytometric cell cycle assay, scratch assay, transwell assay, and molecular docking were used to investigate the inhibitory effect of 3-DSC on HeLa and PC3 cells. The results showed that 3-DSC inhibited the cell migration and invasion by down-regulating expression of N-cadherin, Vimentin, MMP-2, and MMP-9 in HeLa and PC3 cells; It also inhibits cell proliferation by promoting the expression of CDK1 (cyclin-dependent kinases 1) and CDK2 (cyclin-dependent kinases 2), which arrests the tumor cell cycle at G2 phase. 3-DSC inhibits phosphorylation of AKT and ERK and upregulates the expression of the tumor suppressor gene p53. Molecular docking results confirmed that 3-DSC could bind firmly to AKT. In conclusion, 3-DSC inhibited the proliferation, migration and invasion of HeLa and PC3 cells.

Keywords: Caesalpinia sinensis; Cell cycle; Invasion; Migration; Proliferation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Effect of 3-DSC on cell proliferation in HeLa and PC3 cells. A: Chemical structure of 3-DSC. B: SRB cell viability assay. C and D: Clone formation assay. ∗ indicates comparison with 3-DSC free group (0 group), ∗p < 0.05, ∗∗p < 0.01,∗∗∗p < 0.001.
Figure 2
Figure 2
Effect of 3-DSC on migration and invasio in HeLa and PC3 cells. A and B: wound Healing Assay. C and D: Transwell migration. E and F: Transwel invasion. G and H: The proteins expression of N-cadherin, Vimentin, MMP-2, and MMP-9. ∗ indicates comparison with 3-DSC free group (0 group), ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Figure 3
Figure 3
3-DSC effects on cell cycle. A and B: Cell cycle. C: Schematic representation of CDK1 and CDK2 regulation of cell cycle. D and E: The proteins expression of CDK1 and CDK2. ∗ indicates comparison with 3-DSC free group (0 group), ∗p < 0.05, ∗∗p < 0.01,∗∗∗p < 0.001.
Figure 4
Figure 4
Effect of 3-DSC on the mode and mechanism of death of HeLa and PC3. A: SRB cell viability assay to detect the mode of death. B and C: The proteins expression of AKT, p-ERK and p53. D and E: Molecular docking results of 3-DSC with AKT. Z-VAD-FMK is a Pan-Caspase inhibitor; MHY1485 is a potent, cell-permeable mTOR agonist that also effectively inhibits autophagy; Fer-1 (Ferrostatin-1) is a potent and selective inhibitor of ferroptosis; Nec-1 (Necrostatin-1) is a specific RIP1 (RIPK1) inhibitor that inhibits cell necrosis; Lip-1 (Liproxstatin-1) is a potent inhibitor of ferroptosis. ∗ indicates comparison with 3-DSC free group (0 group), ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

Similar articles

Cited by

References

    1. Zhang Y., Liu Z. Oncolytic virotherapy for malignant tumor: current clinical status. Curr. Pharmaceut. Des. 2019;25:4251–4263. - PubMed
    1. Chen W. Cancer statistics: updated cancer burden in China. Chin. J. Cancer Res. 2015;27:1. - PMC - PubMed
    1. Meijer C.J., Snijders P.J. Cervical cancer in 2013: screening comes of age and treatment progress continues. Nat. Rev. Clin. Oncol. 2014;11:77–78. - PubMed
    1. Komura K., Sweeney C.J., Inamoto T., Ibuki N., Azuma H., Kantoff P.W. Current treatment strategies for advanced prostate cancer. Int. J. Urol. 2018;25:220–231. - PMC - PubMed
    1. Daugėlaitė G., Užkuraitytė K., Jagelavičienė E., Filipauskas A. Prevention and treatment of chemotherapy and radiotherapy induced oral mucositis. Medicina (Kaunas) 2019;55 - PMC - PubMed